Good Clinical Practice inspection findings follow recognizable patterns across therapeutic areas and sponsor types, and a meaningful share of the most common findings are preventable through process changes made well before an inspector arrives, rather than through better performance during the inspection itself.
Informed consent documentation issues remain among the most frequently cited findings, often involving consent forms that were not properly re-consented following a protocol amendment, or documentation gaps around when a specific version of the consent form was actually used with a specific patient. Building a systematic version-control process for consent documentation at the site level substantially reduces this risk.
Source document verification discrepancies, where data recorded in the case report form does not match the underlying source documentation at the site, frequently stem from inadequate site training on what constitutes acceptable source documentation for a specific data point, rather than from deliberate data manipulation. Clear, protocol-specific source documentation guidance provided during site initiation visits addresses much of this risk before it becomes a pattern.
Investigational product accountability findings, gaps in the chain of custody documentation for study drug from receipt through dispensing and return or destruction, often reflect inadequate site pharmacy training or unclear responsibility assignment at sites where the same staff handle multiple concurrent trials with different accountability requirements.
Protocol deviation reporting delays are a recurring finding that usually reflects a site-level process gap rather than a monitoring failure, since sites sometimes lack clarity on what threshold of deviation requires formal reporting versus internal documentation only, a distinction that benefits from explicit, written guidance specific to each protocol rather than reliance on general GCP training alone.
Coverage examining inspection findings across multiple sponsors and identifying the systemic process gaps behind recurring citation categories, rather than treating each finding as an isolated site failure, such as the analysis regularly published by The Clinical Trial Vanguard, gives quality teams a more useful basis for proactive process improvement than reacting to findings after they occur.
